Study of a new medication for adults with bronchiectasis
Part of Lungs & breathing clinical trials.
This study tests a new medication called Galvokimig to see if it helps reduce lung infections and improve quality of life in adults with bronchiectasis (a condition where lung airways are damaged and fill with mucus). It is a 24 to 52 week treatment, and you will be monitored closely for safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old
- You must have a confirmed diagnosis of bronchiectasis (not due to cystic fibrosis) with symptoms like cough, mucus, or repeated chest infections
- You need to be able to cough up mucus on your own
- You must have had at least 2 moderate or severe chest flare-ups in the last year (or 1 severe one in the last 6 months)
- Your lung function should be at least 30% of normal (measured by a breathing test)
- If you are of childbearing age, you must agree to use contraception during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an inhaled medication called CSL787 to see if it can help people with non-cystic fibrosis bronchiectasis (a lung condition that causes frequent infections and breathing problems). The study looks at different doses and checks how well the drug works and if it is safe.
This trial tests a new medicine, HSK31858, for people with non-cystic fibrosis bronchiectasis (a lung condition causing chronic cough and infections). It aims to see if the drug reduces lung flare-ups and improves symptoms.
This study tests an inhaled medicine (GDC-6988) to see if it is safe and helps clear mucus from the lungs in people with mucus-related lung diseases like chronic bronchitis, COPD, or bronchiectasis. You may qualify if your lung function is fairly stable and you produce daily mucus.
This study tests whether an investigational tablet called XH-S004 can reduce flare-ups and improve symptoms in people with bronchiectasis (widened airways that trap mucus). It is for adults who produce phlegm daily and have had at least two worsening episodes in the last year.
This study tests how safe an experimental inhaled medicine (HSK31858) is for people with non-cystic fibrosis bronchiectasis, a lung condition where airways are damaged and collect mucus. You can only join if you already completed a previous HSK31858 study.
This study tests an experimental drug called Galvokimig (taken as a pill) to see if it can reduce COPD flare-ups and improve lung function in people with moderate to severe COPD and chronic bronchitis. It is for those who have had recent flare-ups and are already using maintenance inhalers.
Hear when a new Non-cystic Fibrosis Bronchiectasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.